Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -29.57% is in line with its 5-year average of -32.14%, around the middle of its 5-year range (-44.50%–-6.55%).
28.97% above its 12-month average of -41.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.65%.
RETURN ON ASSETS (ROA)
-29.57%
RETURN ON ASSETS (ROA) AVG TTM
-41.63%
RETURN ON ASSETS (ROA) AVG 3Y
-37.55%
RETURN ON ASSETS (ROA) AVG 5Y
-32.14%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.97%
CURRENT VS 3Y AVG
+21.25%
CURRENT VS 5Y AVG
+7.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
+7.42%
vs the sector median at left
Relay Therapeutics, Inc.
Market Cap
$4.00B
Return on Assets (ROA)
-29.57%
TTM Avg
-41.63%
3Y Avg
-37.55%
5Y Avg
-32.14%
Market Cap
$4.05B
Return on Assets (ROA)
-12.59%
TTM Avg
-11.38%
3Y Avg
-5.58%
5Y Avg
0.19%
Market Cap
$3.95B
Return on Assets (ROA)
0.76%
TTM Avg
-1.39%
3Y Avg
-1.28%
5Y Avg
0.88%
Market Cap
$4.14B
Return on Assets (ROA)
7.14%
TTM Avg
-3.40%
3Y Avg
-2.46%
5Y Avg
-5.09%
Market Cap
$3.79B
Return on Assets (ROA)
-62.27%
TTM Avg
-56.63%
3Y Avg
-50.24%
5Y Avg
-125.83%
Market Cap
$4.28B
Return on Assets (ROA)
-41.11%
TTM Avg
-28.92%
3Y Avg
-26.43%
5Y Avg
-22.29%
Market Cap
$4.41B
Return on Assets (ROA)
-9.97%
TTM Avg
-20.59%
3Y Avg
-24.65%
5Y Avg
-22.36%
Market Cap
$4.41B
Return on Assets (ROA)
28.79%
TTM Avg
8.79%
3Y Avg
1.95%
5Y Avg
1.56%
Market Cap
$4.43B
Return on Assets (ROA)
-34.36%
TTM Avg
-56.86%
3Y Avg
-55.14%
5Y Avg
-55.14%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | $4.00B | -29.57% | -41.63% | -37.55% | -32.14% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.05B | -12.59% | -11.38% | -5.58% | 0.19% |
| ICU Medical, Inc. (ICUI)vs › | $3.95B | 0.76% | -1.39% | -1.28% | 0.88% |
| LivaNova PLC (LIVN)vs › | $4.14B | 7.14% | -3.40% | -2.46% | -5.09% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.79B | -62.27% | -56.63% | -50.24% | -125.83% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | -41.11% | -28.92% | -26.43% | -22.29% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | -9.97% | -20.59% | -24.65% | -22.36% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | 28.79% | 8.79% | 1.95% | 1.56% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | -34.36% | -56.86% | -55.14% | -55.14% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | -1.28% | -8.27% | -17.73% | -16.90% |
ROA
-29.6%
ROE
-32.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -44.50% |
| 2024-12-31 | -38.76% |
| 2023-12-31 | -40.52% |
| 2022-12-31 | -26.42% |
| 2021-12-31 | -36.08% |
| 2020-12-31 | -6.55% |
| 2019-12-31 | -16.92% |
| 2018-12-31 | -11.38% |
